U.S. Markets closed

Evaxion Biotech A/S (EVAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.40-0.08 (-1.46%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.48
Open5.62
Bid5.26 x 1100
Ask5.40 x 1000
Day's Range5.39 - 5.67
52 Week Range5.16 - 10.34
Volume29,891
Avg. Volume79,198
Market Cap103.673M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.50
  • Evaxion's Cancer Immunotherapy Shows Antitumor Effect In Early-Stage Melanoma Study
    Benzinga

    Evaxion's Cancer Immunotherapy Shows Antitumor Effect In Early-Stage Melanoma Study

    Evaxion Biotech A/S (NASDAQ: EVAX) has announced results from its Phase 1/2a trial of EVX-01 in metastatic melanoma. Data from the trial showed that EVX-01 in combination with a PD-1 checkpoint inhibitor was safe, with only mild and moderate adverse events observed. Combined therapy with EVX-01 demonstrated an objective response rate of 67% across all nine patients, including 22% Complete Response (CR) and 44% Partial Response (PR). Among the four patients on the highest two doses, there was an

  • Evaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02
    GlobeNewswire

    Evaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02

    New clinical data demonstrates antitumor effect of EVX-01 in combination with anti-PD1 treatmentObjective Response Rate (ORR) of 67% with EVX-01 + anti-PD1 treatment in nine metastatic melanoma patients, including 22% Complete Response (CR) and 44% Partial Response (PR)Clinical trial data supports the proprietary AI-Immunology platform, PIONEER, with regard to: neoepitope prediction, de novo T-cell activation and clinical response in cancer patients Phase 2 trial of EVX-01 in melanoma, planned t

  • Evaxion Biotech to Host Conference Call on EVX-01 and EVX-02 Phase 1/2a Data on July 8
    GlobeNewswire

    Evaxion Biotech to Host Conference Call on EVX-01 and EVX-02 Phase 1/2a Data on July 8

    COPENHAGEN, Denmark, July 07, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today that it will hold a conference call to discuss Phase 1/2a data on EVX-01 and EVX-02 on Thursday, July 8, 2021. Lars Wegner, CEO of Evaxion, Glenn Vraniak, CFO, and Niels Iversen Moller, co-founder and CBO,